Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 18;24(3):575.
doi: 10.3892/etm.2022.11512. eCollection 2022 Sep.

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis

Liang Xu  1 , Weifan Jiang  2 , Wenwei Li  1 , Chungen Guo  1 , Lihua Luo  1 , Yufeng Gao  3 , Yali Cao  1
Affiliations

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis

Liang Xu et al. Exp Ther Med. .

Abstract

Currently, endocrine therapy is the standard treatment for hormone receptor-positive advanced breast cancer (ABC). Despite the high sensitivity of anti-estrogen therapy, many breast cancer patients still experience disease progression, relapse, and reduced overall survival (OS) because of endocrine resistance. Several underlying mechanisms of this phenomenon include a change in hormone receptor expression, mutations in ESR1 and modification of important signaling pathways, but thus far none of these can be defined as the complete explanation. Additionally, it has been shown that in some breast cancers, expression of the estrogen receptor (ER) can be repressed by epigenetic modifications such as DNA methylation and histone deacetylation, and this could be a mechanism for endocrine resistance. Interestingly, although the efficacy of the combination of histone deacetylase (HADC) inhibitors and exemestane in hormone receptor-positive ABC that progressed on prior endocrine therapy has been investigated in several studies, whether pharmacologic blocking of HDAC activity acts as a therapeutic strategy remains highly controversial. Herein, we conducted a meta-analysis to evaluate the efficacy and safety of an HDAC inhibitor plus exemestane vs. exemestane alone in this setting. Our meta-analysis demonstrated that the combination group exhibited significantly prolonged progression-free survival (PFS) [hazard ratio (HR)=0.776, 95% confidence interval (CI)=0.675-0.892, P=0.000] and an improved objective response rate (ORR) (RR=1.612, 95% CI=1.085-2.396, P=0.018) compared to those treated with exemestane alone. Additionally, in terms of OS, the combination group failed to achieve a significant clinical OS benefit (HR=0.811, 95% CI=0.596-1.104, P=0.183). Although grade 3/4 toxicities were more common in the combination group, those toxicities were mostly asymptomatic and manageable. In conclusion, the addition of an HDAC inhibitor to exemestane significantly improves PFS over exemestane alone in hormone receptor-positive ABC patients who progressed on previous endocrine therapy. Identification of novel biomarkers to select patients who will benefit from this combination strategy is a high priority.

Keywords: breast cancer; combination therapy; endocrine resistance; histone deacetylase inhibitors; metastasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow diagram and results of our literature search.
Figure 2
Figure 2
The pooled HR and 95% CI for PFS in the combination group and exemestane group. Combination therapy, a histone deacetylase inhibitor plus exemestane; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival.
Figure 3
Figure 3
The pooled HR and 95% CI for OS. Combination therapy, a histone deacetylase inhibitor plus exemestane; HR, hazard ratio; CI, confidence interval; OS, overall survival.
Figure 4
Figure 4
The pooled RR and 95% CI for ORR. Combination therapy, a histone deacetylase inhibitor plus exemestane; RR, risk ratio; CI, confidence interval; ORR, overall response rate.
Figure 5
Figure 5
Forest plot of relative risk of treatment-induced grade 3-4 toxicities. Combination therapy, a histone deacetylase inhibitor plus exemestane; RR, risk ratio; CI, confidence interval.
Figure 6
Figure 6
Funnel plot of publication bias in the meta-analysis. (A) PFS. (B) ORR. HR, hazard ratio; PFS, progression-free survival; ORR, overall response rate.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496–513. doi: 10.1016/j.ccell.2020.03.009. - DOI - PMC - PubMed
    1. El Sayed R, El Jamal L, El Iskandarani S, Kort J, Abdel Salam M, Assi H. Endocrine and targeted therapy for hormone-receptor-positive, HER2-Negative advanced breast cancer: Insights to sequencing treatment and overcoming resistance based on clinical trials. Front Oncol. 2019;9(510) doi: 10.3389/fonc.2019.00510. - DOI - PMC - PubMed
    1. Nagaraj G, Ma CX. Clinical challenges in the management of hormone receptor-positive, human epidermal growth factor receptor 2-Negative metastatic breast cancer: A literature review. Adv Ther. 2021;38:109–136. doi: 10.1007/s12325-020-01552-2. - DOI - PMC - PubMed
    1. Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904–916. doi: 10.1016/S1470-2045(17)30376-5. - DOI - PMC - PubMed